Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRX NASDAQ:CING NYSE:MTNB NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.67+3.4%$4.09$2.30▼$26.80$15.13M1.2632,242 shs8,257 shsCINGCingulate$3.90+2.9%$4.49$3.02▼$7.00$20.51M-0.76152,173 shs147,066 shsMTNBMatinas Biopharma$1.72+1.8%$1.30$0.47▼$4.25$8.75M1.41429,008 shs49,236 shsVYNEVYNE Therapeutics$0.30-3.6%$0.80$0.29▼$4.30$7.91M1.81.76 million shs2.08 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+3.38%-3.17%-5.66%-36.06%-85.32%CINGCingulate+2.90%-2.26%-13.72%-10.55%-41.88%MTNBMatinas Biopharma+1.78%-5.49%+91.11%+84.97%+826.23%VYNEVYNE Therapeutics-3.64%-6.65%-18.03%-70.08%-84.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.67+3.4%$4.09$2.30▼$26.80$15.13M1.2632,242 shs8,257 shsCINGCingulate$3.90+2.9%$4.49$3.02▼$7.00$20.51M-0.76152,173 shs147,066 shsMTNBMatinas Biopharma$1.72+1.8%$1.30$0.47▼$4.25$8.75M1.41429,008 shs49,236 shsVYNEVYNE Therapeutics$0.30-3.6%$0.80$0.29▼$4.30$7.91M1.81.76 million shs2.08 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+3.38%-3.17%-5.66%-36.06%-85.32%CINGCingulate+2.90%-2.26%-13.72%-10.55%-41.88%MTNBMatinas Biopharma+1.78%-5.49%+91.11%+84.97%+826.23%VYNEVYNE Therapeutics-3.64%-6.65%-18.03%-70.08%-84.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 3.50Strong Buy$26.00608.45% UpsideCINGCingulate 3.00Buy$26.25573.08% UpsideMTNBMatinas Biopharma 2.00HoldN/AN/AVYNEVYNE Therapeutics 2.00Hold$6.251,988.90% UpsideCurrent Analyst Ratings BreakdownLatest MTNB, VYNE, CING, and BLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.008/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/31/2025VYNEVYNE TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/30/2025VYNEVYNE TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/30/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$28.94M0.54N/AN/A$4.04 per share0.91CINGCingulateN/AN/AN/AN/A$2.32 per shareN/AMTNBMatinas BiopharmaN/AN/AN/AN/A$4.43 per shareN/AVYNEVYNE Therapeutics$500K15.24N/AN/A$3.53 per share0.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-45.34%-49.74%-17.54%11/24/2025 (Estimated)CINGCingulate-$15.55M-$4.10N/AN/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)MTNBMatinas Biopharma-$22.94M-$3.89N/A∞N/AN/A-123.06%-94.28%N/AVYNEVYNE Therapeutics-$39.83M-$0.90N/AN/AN/A-8,097.69%-77.57%-63.09%11/6/2025 (Estimated)Latest MTNB, VYNE, CING, and BLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/A8/14/2025Q2 2025BLRXBioLineRx-$0.35-$1.00-$0.65-$1.00$0.66 million$0.30 million8/14/2025Q2 2025VYNEVYNE Therapeutics-$0.23-$0.13+$0.10-$0.13$0.15 million$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.332.061.87CINGCingulateN/A1.521.52MTNBMatinas BiopharmaN/A5.535.53VYNEVYNE TherapeuticsN/A7.607.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%CINGCingulate41.31%MTNBMatinas Biopharma11.77%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%CINGCingulate4.04%MTNBMatinas Biopharma4.60%VYNEVYNE Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.26 million4.22 millionOptionableCINGCingulate205.41 million5.19 millionNot OptionableMTNBMatinas Biopharma305.09 million4.60 millionN/AVYNEVYNE Therapeutics3025.47 million24.25 millionNot OptionableMTNB, VYNE, CING, and BLRX HeadlinesRecent News About These CompaniesVYNE Therapeutics (NASDAQ:VYNE) Trading 2.7% Higher - Still a Buy?August 28, 2025 | americanbankingnews.comVYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagAugust 19, 2025 | finance.yahoo.comVitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightAugust 14, 2025 | finance.yahoo.comVYNE Therapeutics reports Q2 EPS (13c) vs (22c) last yearAugust 14, 2025 | msn.comVYNE Reports Narrower Loss in Fiscal Q2August 14, 2025 | aol.comAVYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue EstimatesAugust 14, 2025 | zacks.comVYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comVitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future LandscapeAugust 5, 2025 | theglobeandmail.comHere's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash WiselyAugust 1, 2025 | finance.yahoo.comRepibresib gel fails to meet endpoints for nonsegmental vitiligo studyAugust 1, 2025 | healio.comHVyne Therapeutics Ends Trial of Repibresib Gel in Nonsegmental VitiligoJuly 31, 2025 | marketwatch.comVYNE Therapeutics stock falls after vitiligo trial fails to meet endpointsJuly 31, 2025 | za.investing.comHC Wainwright & Co. Downgrades VYNE Therapeutics (VYNE)July 31, 2025 | msn.comVYNE Ends Phase IIb Vitiligo Trial of Repibresib After Missing Primary EndpointJuly 31, 2025 | appliedclinicaltrialsonline.comAVYNE Therapeutics Shares Sink Premarket Following End to Trial After Endpoint MissedJuly 31, 2025 | marketwatch.comVyne's lead BET inhibitor fails phase 2 vitiligo trial, sinking stockJuly 31, 2025 | fiercebiotech.comFVyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye ReboundJuly 31, 2025 | msn.comVYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental VitiligoJuly 30, 2025 | globenewswire.comVyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b ReadoutJuly 28, 2025 | seekingalpha.comVYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline ProgressJuly 11, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AIBy Thomas Hughes | August 14, 2025Costco and Ross: 2 Ways to Play the Consumer DivideBy Chris Markoch | August 24, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025MTNB, VYNE, CING, and BLRX Company DescriptionsBioLineRx NASDAQ:BLRX$3.67 +0.12 (+3.38%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$3.64 -0.04 (-0.95%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Cingulate NASDAQ:CING$3.90 +0.11 (+2.90%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.97 +0.07 (+1.79%) As of 09/5/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Matinas Biopharma NYSE:MTNB$1.72 +0.03 (+1.78%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.67 -0.05 (-2.91%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.VYNE Therapeutics NASDAQ:VYNE$0.30 -0.01 (-3.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.30 +0.00 (+0.27%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
